Cutaneous Melanoma Clinical Trial
Official title:
Imaging Modalities for Melanoma Screening and Diagnosis
Verified date | April 2024 |
Source | OHSU Knight Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial studies how well MoleMapper, Visiomed, and confocal microscopy work in screening participants for melanoma. Analyzing images (photographs) made with three different portable imaging systems may be as good as a visit to a dermatologist's office for finding melanomas before they can spread.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2026 |
Est. primary completion date | May 31, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Persons who participate in the free skin cancer screening at the PDX Skincare Festival at Oregon Health & Science University (OHSU) in 2021/2022 (date pending) and are informed by a provider that they have a pigmented lesion for which a biopsy is recommended are potentially eligible to participate in this study. - Persons who participate in the free skin cancer screening at the War on Skin Cancer event at OHSU in 2021/2022 (date pending) or other dates and locations and are informed by a provider that they have a clinically benign or atypical nevi are eligible to participate in the imaging portion of this study. No biopsy will be offered to these participants. - Persons age 18-80 are eligible for the study - Persons of any race are eligible but we anticipate that most participants will be Non-Hispanic whites due to the prevalence of melanoma and other skin cancers in this group. - Only persons who can provide signed statement of informed consent will be enrolled. - Persons who are identified in OHSU Dermatology clinics or through OHSU e-visit and e-consult platforms as having a skin lesion in need of a biopsy for skin cancer - Persons identified via the Melanoma Community Registry (MCR) (IRB approved: 00010561) Exclusion Criteria: - Allergy to the anesthetic (lidocaine). |
Country | Name | City | State |
---|---|---|---|
United States | OHSU Knight Cancer Institute | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
OHSU Knight Cancer Institute | Oregon Health and Science University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Improvements in virtual triage of patients when enabling patients to take and submit digital dermoscopy images from home | Up to 1 year | ||
Primary | Sensitivity of the imaging modalities | Sensitivity is defined as recommend immediate biopsy (red) lesions correctly identified as red by the dermatologists. The nature of statistical data analyses will be descriptive and exploratory to estimate effect sizes and their variation as well as generate hypotheses for the future study design. Sensitivity and specificity will be estimated along with exact 95% confidence intervals. | Up to 1 year | |
Primary | Specificity of imaging modalities | Specificity is defined as green (follow-up at annual skin exam) or yellow lesions (recommend examination by dermatologist in 3 months) correctly identified. The nature of statistical data analyses will be descriptive and exploratory to estimate effect sizes and their variation as well as generate hypotheses for the future study design. Sensitivity and specificity will be estimated along with exact 95% confidence intervals. | Up to 1 year | |
Secondary | Sensitivity by changes after consideration of in vivo reflectance mode confocal scanning laser microscopy (RCM) report | Secondary analysis will be done with the biopsied lesions that were analyzed by RCM. The dermatologists will be provided a report of the RCM findings as well as the VisioMed images and asked to make the same classification as above. Changes in sensitivity and specificity will be determined. | Up to 1 year | |
Secondary | Specificity by changes after consideration of RCM report | Secondary analysis will be done with the biopsied lesions that were analyzed by RCM. The dermatologists will be provided a report of the RCM findings as well as the Visiomed images and asked to make the same classification as above. Changes in sensitivity and specificity will be determined. | Up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04020809 -
Neoadjuvant Atezolizumab in Cutaneous Melanoma
|
Phase 1 | |
Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
Recruiting |
NCT03767348 -
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
|
Phase 2 | |
Completed |
NCT03628417 -
Confirmatory Trial in the Evaluation of Ca Electroporation for the Treatment of Cutaneous Metastases
|
N/A | |
Withdrawn |
NCT05482074 -
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
|
Phase 2 | |
Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT04551352 -
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
|
Phase 1 | |
Recruiting |
NCT05544929 -
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05628883 -
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
|
Phase 1 | |
Terminated |
NCT04254107 -
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT04830124 -
Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
|
Phase 2 | |
Recruiting |
NCT06319196 -
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
|
Phase 2 | |
Recruiting |
NCT05253872 -
The MELAcare Study: A New Method for Surveillance of Melanoma Patients
|
N/A | |
Recruiting |
NCT04706962 -
TH1902 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04792463 -
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
|
||
Completed |
NCT00679289 -
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
|
Phase 2 | |
Recruiting |
NCT05669430 -
A Study of GV20-0251 in Patients With Solid Tumor Malignancies
|
Phase 1 | |
Recruiting |
NCT04702854 -
Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma
|
N/A |